The invention relates to the pharmaceutical industry, and more particularly to a method for producing a drug based on triticain-α for the treatment of celiac disease. The invention provides improved technological properties of triticain-α, which allows creating the most suitable dosage form for its oral administration (hard hypromellose capsules).